RudaCure signe un accord de développement et d'investissement de 15 milliards de KRW avec Hanlim Pharmaceutical pour le médicament contre la sécheresse oculaire RCI001

Emerging bioventure company RudaCure Inc. (PDG Yongho Kim) a signé a recherche et développement conjoints and investissement accord with Hanlim Pharmaceutical Co., Ltd. (PDG Jaeyoon Kim, Jeongjin Kim), a leading entreprise pharmaceutique in ophtalmique drugs, for the traitement de la sécheresse oculaire RCI001. RCI001, the contrated technology, is a drug that exerts powerful anti-inflammatoire and effets antioxydants through a mechanism that suppresses activation inflammatoire, thereby alleviating sécheresse oculaire. Hanlim Pharmaceutical decided to pursue recherche et développement conjoints of this technology and invest in RudaCure after highly evaluating the commercialization potential of RCI001, sur la base de its faster sécrétion lacrymale, récupération des lésions cornéennes capability, and superior instillation compliance and safety compared to commercially available competing drugs. The total contrat value is KRW 15 billion, comprising a fixed licence fee, separate étape clé-based royalties, and investissement funds. Hanlim Pharmaceutical will be responsible for process development, GMP production, and supply of RCI001, and will secure national sales rights and a certain equity stake in RudaCure. RudaCure will focus on R&D notamment national and international essais cliniques, ainsi que overseas licence. RudaCure prévoit de tirer parti de this partenariat with Hanlim Pharmaceutical to accelerate its pipeline development and pursue global technology licence, targeting successful commercialization of RCI001.

전자신문